Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Canadian Drug Expenditures Reach $31.1B, But Growth in Spending Slows

By Pharmaceutical Processing | May 6, 2011

TORONTO — A new report says
the growth in spending on prescribed and non-prescribed drugs has slowed in Canada, but the
overall tally still came to an estimated $31.1 billion last year.

The Canadian Institute for Health Information says drug
expenditures last year grew $1.4 billion or 4.8 per cent over the previous year
— the lowest rate since 1996.

The average annual growth rate in drug spending was nearly
twice as high between 2000 and 2005, at 8.9 per cent.

An institute official says the slowdown in growth is partly
attributable to blockbuster brand name drugs coming off patent, allowing for
lower-priced generic alternatives to be used instead.

Michael Hunt, the director of pharmaceuticals and health
workforce information services, says the implementation of generic pricing
policies by some provincial drug programs may also be contributing to the
slowdown.

Per capita spending on prescribed and non-prescribed drugs
is forecast to reach $912 per Canadian in 2010.

When only prescribed drugs are considered, per capita
spending ranged from a low of $574 in British Columbia
to a high of $883 in Quebec.

The report, published Thursday, said Canada ranked
as the second highest spender per person compared with 25 other countries in
the Organization for Economic Co-operation and Development in 2008, the latest
year for which comparative figures are available.

CIHI is an independent, not-for-profit organization, funded
by various levels of government, that provides health information to Canadians.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE